ProPhase Labs, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ProPhase Labs, Inc. (PRPH) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-06-01
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $3.37M.
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-09-30 was $0.00.
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $3.37M, a 19.05% decline from fiscal 2023.
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $4.17M, a 41.46% decline from fiscal 2022.
- ProPhase Labs, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $7.12M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 | |||
| 2024-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $3.37M derived: sum of 2 quarters · filed 2026-06-01 | $3.37M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $4.17M 10-K · filed 2025-04-01 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.17M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $4.17M 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.52M derived: sum of 2 quarters · filed 2024-03-29 | $7.12M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $5.60M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |